Angion Biomedica Corp. (ANGN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Angion Biomedica Corp. (ANGN) trades at $1.00 with AI Score 44/100 (Grade C). Angion Biomedica Corp. is a biopharmaceutical company focused on developing therapies for acute organ injuries and fibrotic diseases. Market cap: $30.11M, Sector: Healthcare.
Price live · AI analysis from Jun 1, 2026Analyst Coverage for ANGN: ANGN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ANGN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ANGN: the 1 perspectives are evenly split.
How is this calculated? →Angion Biomedica Corp. (ANGN) Healthcare & Pipeline Overview
Angion Biomedica Corp. is a clinical-stage biopharmaceutical company specializing in small molecule therapeutics for acute organ injuries and fibrotic diseases. Their lead candidate, ANG-3070, aims to address significant unmet needs in kidney and lung fibrosis, positioning them within the competitive biotechnology landscape.
What Is the Investment Thesis for ANGN?
Angion Biomedica presents a high-risk, high-reward investment opportunity within the biotechnology sector. The primary value driver is the clinical progress of ANG-3070, particularly its efficacy and safety data in Phase 2 trials for fibrotic diseases. Successful trial outcomes could lead to significant market potential, given the unmet medical need in kidney and lung fibrosis. However, the company's small market capitalization of $30.11M and limited resources introduce substantial financial risk. Upcoming data readouts from ongoing clinical trials represent key catalysts. The investment thesis hinges on Angion's ability to demonstrate clinical efficacy and secure partnerships or funding to advance its pipeline.
Based on FMP financials and quantitative analysis
ANGN Key Highlights
- Lead product candidate ANG-3070 targets fibrotic diseases, primarily in the kidney and lung, addressing a significant unmet medical need.
- ANG-3777, a hepatocyte growth factor mimetic, is being developed to treat acute organ injuries, such as delayed graft function.
- The company's pipeline includes ROCK2 inhibitors programs for fibrotic diseases, expanding its therapeutic focus.
- Angion Biomedica's focus on small molecule therapeutics allows for potential oral administration and systemic distribution.
- The company is based in Uniondale, New York, and has a small team of 3 employees.
Who Are ANGN's Competitors?
ANGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
| ZYME Zymeworks Inc. | $25.42 | -3.39% | $1.87B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ANGN's Key Strengths?
- Novel drug candidates targeting unmet medical needs.
- Experienced management team with expertise in drug development.
- Proprietary technology platform for small molecule therapeutics.
- Focus on fibrotic diseases and acute organ injuries.
What Are ANGN's Weaknesses?
- Limited financial resources.
- Small number of employees.
- Dependence on clinical trial outcomes.
- High risk of drug development failure.
What Could Drive ANGN Stock Higher?
- Data readouts from Phase 2 clinical trials of ANG-3070 in fibrotic diseases.
- Potential partnerships or collaborations with pharmaceutical companies.
- Continued development of ANG-3777 for acute organ injuries.
- Advancement of ROCK2 inhibitor programs for fibrotic diseases.
What Are the Key Risks for ANGN?
- Financial-distress signal — its Altman Z-Score of -17.97 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Unfavorable clinical trial outcomes for ANG-3070 or ANG-3777.
- Regulatory delays or rejection of drug candidates.
- Competition from other companies developing therapies for fibrotic diseases and organ injuries.
- Limited financial resources to fund ongoing research and development.
What Are the Growth Opportunities for ANGN?
- Advancement of ANG-3070 in Fibrotic Diseases: ANG-3070, an oral tyrosine kinase receptor inhibitor, represents a significant growth opportunity for Angion Biomedica. The market for fibrotic disease treatments is projected to reach billions of dollars by 2030, driven by the increasing prevalence of chronic diseases. Successful completion of Phase 2 trials and subsequent regulatory approval could generate substantial revenue. The company's competitive advantage lies in the potential for ANG-3070 to address the underlying mechanisms of fibrosis, offering a disease-modifying treatment option.
- Development of ANG-3777 for Acute Organ Injuries: ANG-3777, a hepatocyte growth factor mimetic, targets acute organ injuries such as delayed graft function. The market for treatments for acute organ injuries is estimated to grow as the number of organ transplants increases. Positive clinical trial results and subsequent commercialization could provide a valuable revenue stream for Angion Biomedica. The company's focus on a novel mechanism of action differentiates it from existing treatments.
- Expansion of ROCK2 Inhibitor Programs: Angion Biomedica's ROCK2 inhibitor programs offer a potential growth opportunity in the treatment of fibrotic diseases. ROCK2 inhibitors have shown promise in preclinical studies for their ability to modulate inflammation and fibrosis. Successful development and commercialization of these programs could expand the company's therapeutic pipeline and address a broader range of fibrotic conditions. The company's expertise in small molecule drug development provides a competitive advantage.
- Strategic Partnerships and Collaborations: Angion Biomedica can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Collaborations can provide access to additional funding, expertise, and resources, reducing the company's financial risk and increasing its chances of success. The company's innovative pipeline and experienced management team make it an attractive partner for companies seeking to expand their presence in the fibrotic disease market.
- Expansion into New Therapeutic Areas: Angion Biomedica can leverage its expertise in small molecule drug development to expand into new therapeutic areas beyond fibrotic diseases and acute organ injuries. The company's research and development capabilities can be applied to identify and validate novel targets in other disease areas with unmet medical needs. This diversification strategy can reduce the company's reliance on its existing pipeline and create new growth opportunities.
What Opportunities Does ANGN Have?
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
- Positive clinical trial results for lead drug candidates.
- Increasing prevalence of fibrotic diseases and organ injuries.
What Threats Does ANGN Face?
- Competition from other biotechnology and pharmaceutical companies.
- Regulatory hurdles and delays.
- Unfavorable clinical trial outcomes.
- Patent infringement or invalidation.
What Are ANGN's Competitive Advantages?
- Proprietary small molecule therapeutics targeting specific disease pathways.
- Patent protection for drug candidates and related technologies.
- Clinical data supporting the efficacy and safety of its therapies.
- Expertise in drug discovery and development for fibrotic diseases and organ injuries.
What Does ANGN Do?
Angion Biomedica Corp., incorporated in 1998 and based in Uniondale, New York, is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative small molecule therapeutics. The company focuses on addressing critical unmet needs in acute organ injuries and fibrotic diseases. Angion's lead product candidate, ANG-3070, is an oral tyrosine kinase receptor inhibitor currently in development as a treatment for fibrotic diseases, with a primary focus on the kidney and lung. This therapeutic approach aims to modulate key signaling pathways involved in the progression of fibrosis, offering a potential disease-modifying treatment option. In addition to ANG-3070, Angion Biomedica is also developing ANG-3777, a hepatocyte growth factor mimetic designed to treat acute organ injuries, including delayed graft function. The company's pipeline also includes ROCK2 inhibitors programs targeting fibrotic diseases and a CYP11B2 inhibitor program. Angion's strategic focus on small molecule therapeutics allows for potential oral administration and systemic distribution, offering advantages in terms of patient convenience and accessibility. The company's research and development efforts are geared towards identifying and validating novel targets and developing differentiated therapeutic candidates with the potential to improve patient outcomes in areas with limited treatment options.
What Products and Services Does ANGN Offer?
- Discovers and develops small molecule therapeutics.
- Focuses on treatments for acute organ injuries.
- Develops therapies for fibrotic diseases.
- Lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor.
- Developing ANG-3777, a hepatocyte growth factor mimetic.
- Pursues ROCK2 inhibitors programs for fibrotic diseases.
- Works on CYP11B2 inhibitor program.
How Does ANGN Make Money?
- Develops and patents novel small molecule therapeutics.
- Conducts preclinical and clinical trials to evaluate drug candidates.
- Seeks regulatory approval from agencies like the FDA.
- Aims to commercialize approved drugs directly or through partnerships.
What Industry Does ANGN Operate In?
Angion Biomedica operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant clinical trial risks. The market for fibrotic disease treatments is substantial, driven by the increasing prevalence of chronic diseases such as chronic kidney disease and idiopathic pulmonary fibrosis. Key industry trends include the development of targeted therapies, personalized medicine approaches, and the use of biomarkers to identify patients most likely to respond to treatment. Angion Biomedica's focus on small molecule therapeutics and its pipeline of novel drug candidates position it to potentially capture a share of this growing market.
Who Are ANGN's Key Customers?
- Patients suffering from fibrotic diseases (kidney, lung).
- Patients with acute organ injuries.
- Healthcare providers who prescribe and administer the company's therapies.
- Potential pharmaceutical partners for licensing or co-development agreements.
Company Profile
Angion Biomedica Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Uniondale, US. The company is led by CEO Jay R. Venkatesan. ANGN has traded publicly since 2021.
Angion Biomedica Corp. (ANGN) Valuation Context
Valued at $30.11M, ANGN is classified as a micro-cap stock. Relative to its peer group, ANGN's quantitative score of 44/100 is below the peer average of 76/100.
F-Score 3/9Financial Health
Angion Biomedica Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -17.97 places it in the distress zone, a signal of elevated financial risk.
Net buyingInsider Activity
The most recent 11 insider filings for Angion Biomedica Corp. break down as 3 sales and 8 purchases. On net that is roughly 1.2M shares acquired (about $7.2M) — insiders putting money in tends to read as conviction.
ANGN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Angion's recent insider buying suggests those in the know see value, hinting at potential future growth.
- The community buzz is leaning bullish, with many seeing long-term potential in their pipeline.
- Market perception seems to be improving, with more analysts acknowledging the company's innovative approach.
- Angion's focus on kidney disease and related complications aligns with a growing need in the healthcare sector.
Bear Case
- Despite insider buying, some worry about the long road to revenue given the clinical trial stages.
- The community, while generally optimistic, also expresses concerns about competition in the biotech space.
- Market perception is still somewhat cautious due to past trial setbacks, creating lingering doubts.
- Angion's reliance on successful trial outcomes makes it vulnerable to negative news, impacting investor confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ANGN Latest News
ANGN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ANGN.
Price Targets
Wall Street price target analysis for ANGN.
ANGN MoonshotScore
What does this score mean?
The MoonshotScore rates ANGN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jay R. Venkatesan
Unknown
Information about Jay R. Venkatesan's background is not available in the provided data. Without additional context, it is impossible to provide details about his career history, education, or previous roles.
Track Record: Information about Jay R. Venkatesan's track record is not available in the provided data. It is unknown what key achievements, strategic decisions, or company milestones have occurred under his leadership.
Common Questions About ANGN (Healthcare)
What does Angion Biomedica Corp. do?
Angion Biomedica Corp. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. Their lead product candidate, ANG-3070, is an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. The company also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function. Angion's business model centers on advancing its pipeline of drug candidates through clinical trials and seeking regulatory approval for commercialization.
What are the key growth opportunities for ANGN in healthcare?
Angion Biomedica's growth opportunities lie in the successful development and commercialization of its pipeline of drug candidates. Specifically, the advancement of ANG-3070 through Phase 2 and Phase 3 clinical trials for fibrotic diseases represents a significant growth driver. Positive clinical data and subsequent regulatory approval could lead to substantial revenue generation. Additionally, the development of ANG-3777 for acute organ injuries and the expansion of ROCK2 inhibitor programs offer further growth potential within the healthcare sector. Strategic partnerships and collaborations with larger pharmaceutical companies could also accelerate the company's growth trajectory.
What are the main risks for ANGN?
Angion Biomedica faces several risks inherent in the biotechnology industry. Clinical trial failures for its lead drug candidates, ANG-3070 and ANG-3777, represent a significant risk. Regulatory hurdles and delays in obtaining approval from agencies like the FDA could also impede the company's progress. Competition from other companies developing therapies for fibrotic diseases and organ injuries poses a threat to Angion's market share. Furthermore, the company's limited financial resources and small number of employees create operational and financial risks.
What are the key factors to evaluate for ANGN?
Angion Biomedica Corp. (ANGN) holds an AI score of 44/100 (low). Not financial advice.
How frequently does ANGN data refresh on this page?
ANGN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ANGN's recent stock price performance?
Angion Biomedica Corp. (ANGN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel drug candidates targeting unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ANGN overvalued or undervalued right now?
Valuing Angion Biomedica Corp. (ANGN) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ANGN?
Before investing in Angion Biomedica Corp. (ANGN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data sources.
- Financial projections are not available.
- Clinical trial outcomes are uncertain.